Chromis Therapeutics

Chromis Therapeutics Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing curative treatments for chronic hepatitis B virus (HBV) infection. The company focuses on innovative antiviral therapies, including a cccDNA inhibitor, a viral entry inhibitor, and a core assembly inhibitor, all currently in preclinical development. Among its lead candidates is CHR101, a novel cccDNA inhibitor that shows promise in eradicating HBV and curing chronically infected patients more effectively than existing treatments. Chromis leverages its proprietary drug design and discovery platform to advance these therapies, aiming to provide patients with effective solutions that minimize side effects. The company is actively seeking investment to propel its research and development efforts.